Trial Profile
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-finding Phase II Study of Subcutaneously Administered IFN-beta-1a in the Treatment of Patients With Moderately Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors EMD Serono
- 10 May 2014 New trial record